首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷生技設備

市場調查報告書

商品編碼

1542918

全球生物成像技術市場 - 2024-2031

Global Bio Imaging Technologies Market - 2024-2031

出版日期: 2024年08月26日 | 出版商:

DataM Intelligence | 英文 200 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

生物成像技術市場規模

全球生物成像技術市場2023年達到59.4億美元，預計到2031年將達到176億美元，2024-2031年預測期間複合年成長率為15.3%。

生物成像技術是提供生物製程非侵入性可視化的方法。多種技術可用於成像目的。這些技術盡可能減少對生命過程的干擾，並在沒有任何物理干擾的情況下提供樣本 3D 結構的資料。

生物成像技術市場動態

推動全球生物成像技術市場的主要因素是慢性疾病的增加、研發和臨床試驗的增加以及技術的進步。新穎產品推出的增加有助於生物成像技術市場的成長。

研發投資的增加和進步以及新穎產品的推出預計將推動市場的成長。

這些生物影像技術產品擴大用於診斷、預防或治療各種慢性疾病（例如神經退化性疾病和癌症），以及不斷增加的新產品發布推動了生物成像技術市場。癌症發生率的增加也有助於市場成長。許多醫療保健公司增加了研發活動來開發新產品。

生物影像技術用於各種疾病的診斷、預防或治療目的。由於案例數量不斷增加，這些技術的應用市場在全球範圍內不斷擴大。此外，主要參與者提供技術先進的產品預計也將在市場的成長中發揮至關重要的作用。

各種新產品的推出、監管部門的批准和研究都有助於市場的成長。例如，2022 年 8 月 3 日，雅培宣布其由 Ultreon Software 支援的新型光學相干斷層掃描成像平台 (OCT) 已獲得美國食品藥物管理局的批准。這是一款創新的影像軟體，將人工智慧（AI）與OCT相結合，為醫生提供高而全面的冠狀動脈血流量和遮擋視野，以協助他們決策並提供最佳治療途徑。

生物成像技術的高成本預計將阻礙市場的成長。

然而，這些生物成像技術的高成本是限制市場成長的主要因素。其他限制包括高輻射劑量輸送，長期來看可能導致遺傳性疾病。

通常將輻射劑量調整為所需的目標輻射，但仍可能誘發癌症。探針和染料的添加會干擾脂質囊泡的特性，並可能導致實驗假象，導致資料解釋不準確。

COVID-19 對生物影像技術市場的影響

疫情對全球金融預期、營運和危機應對策略產生了積極影響。 COVID-19 的爆發嚴重影響了醫療保健產業。由於新冠肺炎，生物成像技術市場獲得了巨額利潤，因為各種研究和診斷中心開始啟動，並且由於新冠病例及其診斷的不斷增加，對這些技術的需求也隨之增加。全球正在發生多項措施、產品發布、創新、合作和合併，推動了市場的成長。例如，2022 年6 月14 日，邁瑞宣佈在2022 年歐洲麻醉展上推出其新型TEX20 系列超音波系統。的資訊解決方案、智慧工具和以臨床為導向的工作流程，經過深思熟慮的設計。

生物成像技術市場細分分析

奈米生物成像領域預計在預測期內（2024-2031）將以最快的複合年成長率成長

奈米生物成像領域是全球生物成像技術市場中最大的市場佔有者。全球生物成像技術市場根據技術類型進行細分：奈米生物成像、光學成像、正電子發射斷層掃描、磁振造影、超音波成像、電腦斷層掃描、放射成像等。奈米生物成像領域因其更好的功效和結果、優於其他技術的優勢以及這些生物成像技術的不斷進步和採用而成為最大的市場佔有率。

奈米技術可以解決高解析度影像建構的障礙。奈米技術可以將正子斷層掃描技術的進步提升到一個新的水平，因為它可以最大限度地提高目前可用技術的解析度。奈米生物成像可以藉助獨特設計的奈米結構來提高目標成像特異性。在醫學和螢光生物成像研究中，奈米材料的增強作用反映了奈米技術對生物成像的影響。最重要的是，奈米生物成像技術或成像與奈米粒子的組合提供了改進的對比影像。各種生物相容性奈米晶體和小分子造影劑可以提供強大的成像訊號。

越來越多的監管批准、技術進步、產品發布和研究/臨床試驗研究推動了市場的成長。例如，2022 年9 月12 日，Clario 探索了神經影像或神經黑色素MRI 和Opal 感測器技術的益處，因為它提高了臨床結果測量的精度和質量，因此在帕金森氏症國際大會上描述了分散臨床試驗的數字終點疾病和運動障礙 2022。

生物成像技術市場地域佔有率

北美在全球生物成像技術市場中佔有最大的市場佔有率。

北美在全球生物成像技術市場佔據主導地位，這主要是由於其人口眾多、醫療基礎設施完善以及慢性疾病數量不斷增加。根據美國癌症協會估計，到 2022 年，美國將出現約 60,650 例新的白血病病例，其中 24,000 例死亡。 65 歲或以上的人中，約有九分之一患有失智症；到 2050 年，這一數字預計將達到 1,270 萬人左右。越來越多的大腦健康問題、心血管疾病和癌症病例增加了對生物成像技術的需求。

醫療保健支出的增加和人們意識的提高也促進了該地區市場的成長。生物影像技術在多種疾病診斷和檢查中的應用取得進展，為進一步研究提供人體生理學資料庫，區域內製藥機構和政府核准的增加，以及該領域關鍵參與者的存在該地區正在為生物成像技術市場的成長做出貢獻。

此外，產品發布數量的增加也是市場成長的原因。該地區正在發生許多重要的發展、監管批准、技術進步、合作和協議。例如，2021 年 5 月 28 日，醫療設備和解決方案開發商和提供者邁瑞推出了新型普通影像、心臟病和女性醫療保健超音波解決方案。其開發目的是為了提高診斷證據的強度，以確保改善患者護理。

生物成像技術市場公司及競爭格局

生物成像技術市場與本地和全球公司的競爭非常激烈。 GE Healthcare、Abbott Laboratories、Hitachi Medical Corporation、Bayer AG、Esaote SpA、Clario、Digirad Corporation、Bracco、深圳邁瑞生物醫療電子有限公司、Hologic Inc.、FONAR Corporation 等。主要參與者正在採取各種成長策略，例如產品發布、併購、合作夥伴關係和協作，為市場的成長做出貢獻。例如，2021 年 3 月 31 日，MR 掃描投資者 FONAR Corporation 宣布收購紐約州揚克斯市的一家站立式 MRI 設施，FONAR 的診斷影像管理子公司 Health Management Company of America 將從該設施提供非紐約MRI醫療管理服務。

通用電氣醫療保健。

概述：GE醫療保健是通用電氣的子公司，通用電氣是一家融入紐約的美國跨國企業集團，成立於1994年，總部位於伊利諾州芝加哥。它生產和分銷各種診斷成像劑和放射性藥物，可用於某些程序（例如醫學成像）中的成像方式。

產品組合：

SIGNA MR：Signa 是一款 MR 產品，透過高效的生產力和掃描工作流程解決方案增強了磁振造影的功能，並為先進的臨床程序提供了創新。

主要進展：2022 年 10 月，GE Healthcare 在歐洲核子醫學會年度會議上推出了 Omni Legend。該系統首次出現在其全新的數位 PET/CT 平台上，因為它採用最新的晶體尺寸數位 BGO 探測器材料類別，能夠提供比以前的數位掃描儀高兩倍的靈敏度。

全球生物成像技術市場報告將提供約：45 個以上的市場資料表、40 個以上的圖表和 200 個（大約）頁數。

Bio-imaging technologies are the methods that provide non-invasive visualization of biological processes. Several technologies can be used for imaging purposes. These technologies interfere with the life processes as minimally as possible and provide data on the 3D structure of the sample without any physical interference.

Bio-Imaging Technologies Market Dynamics

The major factors driving the global bio-imaging technologies market are increased chronic disorders, rising research and development and clinical trials, and technological advancements. An increase in novel product launches contributes to the growth of the bio-imaging technologies market.

The increasing investment and advancements in R&D and rising novel product launches are expected to drive the market's growth.

The rising adoption of these bio-imaging technologies products for the diagnosis, prevention, or treatment of various chronic disorders, such as neurodegenerative disorders and cancer, and the rising number of novel product launches drive the bio-imaging technologies market. An increase in the incidence of carcinomas is also aiding market growth. There has been an increase in R&D activities by many healthcare companies to develop novel products.

Bio-imaging technologies are used in various diseases for diagnostic, preventive, or treatment purposes. The market for the applications of these technologies is increasing worldwide due to the increasing number of cases. Moreover, the availability of technologically advanced products by key players is also expected to play a vital role in the market's growth.

Various novel product launches, regulatory approvals, and research studies contribute to the market's growth. For instance, in August 3, 2022, Abbott announced that its novel optical coherence tomography imaging platform (OCT), Ultreon Software powered, had received clearance from the U.S. Food and Drugs Administration. This is an innovative imaging software that combines artificial intelligence (AI) with OCT to provide high and comprehensive coronary blood flow, and blockages view to physicians to assist their decision-making and offer the best pathway of treatment.

The high cost associated with bio-imaging technologies is expected to hamper the market's growth.

However, the high cost of these bio-imaging technologies is the leading factor restraining the market's growth. Other limitations include high radiation dose delivery that can lead to genetic disorders in the long term.

The radiation dose is generally adjusted at the desired target radiation but can still induce cancer. The probes and dye addition interferes with lipid vesicle properties and can cause experimental artifacts that result in an inaccurate interpretation of data.

COVID-19 Impact on Bio-Imaging Technologies Market

The pandemic has positively impacted global financial expectations, operations, and crisis response strategy. The COVID-19 outbreak has severely affected the healthcare industry. The bio-imaging technologies market has experienced huge profits due to COVID, as various research and diagnostic centers started and demand for these technologies rose due to the increasing cases of COVID and its diagnosis. Multiple initiatives, product launches, innovations, collaborations, and mergers are happening worldwide, boosting the market's growth. For instance, in June 14, 2022, Mindray announced the launch of its novel TEX20 Series ultrasound system at the Euroanaesthesia 2022. This system has improved features than its predecessors as it provides high image clarity, patient-centered information solution, intelligent tools, and clinical-oriented workflow with thoughtful design.

Bio-Imaging Technologies Market Segment Analysis

The nano bio-imaging segment is expected to grow at the fastest CAGR during the forecast period (2024-2031)

The nano bio-imaging segment is the highest market holder in the global bio-imaging technologies market. The global bio-imaging technologies market is segmented based on technology type: nano bio-imaging, optical imaging, Positron Emission Tomography, magnetic resonance imaging, ultrasound imaging, computed tomography, radiological imaging, and others. The nano bio-imaging segment is the largest market shareholder due to its better efficacy and results, advantages over other technologies, and rising advancements and adoption of these bio-imaging technologies.

Nanotechnology can solve the high-resolution image construction barrier. Nanotechnology can take Positron Emission Tomography advancements to the next level as it can maximize the resolution in currently available techniques. Nano bio-imaging can increase the target imaging specificity with the help of uniquely designed nano constructs. In medical and Fluorescence Bioimaging research, the enhanced role of nanomaterials reflects nanotechnology's impact in bioimaging. The nano bio-imaging technique or combination of imaging and nanoparticle, most importantly, provides improved contrast images. Various biocompatible nanocrystals and small molecule contrast agents can offer strong imaging signals.

The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market's growth. For instance, in September 12, 2022, Clario explored neuroimaging or neuromelanin MRI and Opal sensor tech can be beneficial as it improves the precision and quality of the clinical outcome measures hence, characterizing the digital endpoints for decentralized clinical trials at the International Congress of Parkinson's Disease and Movement Disorders 2022.

Bio-Imaging Technologies Market Geographical Share

North America holds the largest market share in the global bio-imaging technologies market.

North America dominates the global bio-imaging technologies market, primarily due to its large population, excellent medical infrastructure, and rising number of chronic disorders. According to the American Cancer Society, in 2022, Around 60.650 estimated novel leukemia cases will occur, out of which 24,000 deaths will appear in the United States. About 1 out of 9 people 65 years or older have dementia; by 2050, this is expected to reach around 12.7 million. The increasing number of brain health issues, cardiovascular disorders, and cancer cases boost the demand for bio-imaging technologies.

Increasing expenditure on healthcare and raising awareness among people are also contributing to the market's growth in this region. Advancement of applications of bio-imaging technologies in the diagnosis and examination of several diseases, providing the database of the physiology of the human body for further studies, increase in pharmaceutical establishment across the region and government approvals, and the presence of key players in the region are contributing to the growth of the Bio-Imaging Technologies market.

Moreover, the growing number of product launches is responsible for the market's growth. Many vital developments, regulatory approvals, technological advancements, collaborations, and agreements are taking place in this region. For instance, in May 28, 2021, Mindray, medical devices and solutions developer and provider, launched its novel general imaging, cardiology, and women's healthcare ultrasound solutions. This is developed to increase the diagnostic evidence strength for ensuring improved patient care.

Bio-Imaging Technologies Market Companies and Competitive Landscape

The bio-imaging technologies market is highly competitive with local and global companies' presence. GE Healthcare, Abbott Laboratories, Hitachi Medical Corporation, Bayer AG, Esaote S.p.A, Clario, Digirad Corporation, Bracco, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Hologic Inc., FONAR Corporation, and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in March 31, 2021, FONAR Corporation, an MR Scanning investor, announced its acquisition of a Yonkers, New York-based Stand-Up MRI facility from where Health Management Company of America, FONAR's diagnostic imaging management subsidiary will offer non-medical management services for MRI of New York.

GE Healthcare.

Overview: GE HealthCare is a subsidiary of General Electric, an American multinational conglomerate integrated into New York, founded in 1994 and headquartered in Chicago, Illinois. It manufactures and distributes various diagnostic imaging agents and radiopharmaceuticals that can be used for imaging modalities in some procedures, such as medical imaging.

Product Portfolio:

SIGNA MR: Signa is the MR product that increases the capabilities of magnetic resonance imaging with efficient productivity and workflow solutions for scanning and offers innovations to advanced clinical procedures.

Key Developments: In Oct 2022, GE Healthcare introduced Omni Legend at the annual European Nuclear Medicine Associations meeting. This system is first on its all-novel and digital PET/CT platform as it features the latest, crystal-size digital BGO detector material category capable of providing two times more sensitivity than prior digital scanners.

The global bio-imaging technologies market report would provide access to approx.: 45+ market data tables, 40+ figures, and 200 (approximate) pages.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

4.1. Market Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing number of clinical trials
  - 4.1.1.2. Rising technological advancements
- 4.1.2. Restraints:
  - 4.1.2.1. High cost of bio-imaging
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis

6. COVID-19 Analysis

6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer's Strategic Initiatives
6.6. Conclusion

7. By Technology Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
- 7.1.2. Market Attractiveness Index, By Technology Type
7.2. Nano-Bio Imaging *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Optical Imaging
7.4. Positron Emission Tomography
7.5. Magnetic Resonance Imaging
7.6. Ultrasound Imaging
7.7. Computed Tomography
7.8. Radiological Imaging
7.9. Fluorescence Bioimaging
7.10. Others

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Medical Bio-Imaging *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Molecular Bio-Imaging

9. By End-User

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Diagnostic Centers
9.4. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. U.K.
  - 10.3.6.3. France
  - 10.3.6.4. Italy
  - 10.3.6.5. Spain
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
10.5. Asia Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. China
  - 10.5.6.2. India
  - 10.5.6.3. Japan
  - 10.5.6.4. Australia
  - 10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Products Benchmarking
11.4. List of Key Companies to Watch

12. Company Profiles

12.1. GE Healthcare *
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Key Highlights
- 12.1.4. Financial Overview
12.2. Abbott Laboratories
12.3. Hitachi Medical Corporation
12.4. Bayer AG
12.5. Esaote S.p.A
12.6. Clario
12.7. Digirad Corporation
12.8. Bracco
12.9. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
12.10. Hologic Inc.
12.11. FONAR Corporation(*LIST NOT EXHAUSTIVE)